Pediatricians prefer Merck, GSK and Sanofi, says SDI study
When asked how Sanofi had garnered their favor this year, nearly 40% of the physicians surveyed credited the company's vaccines or immunization support programs. Sanofi ramped up detailing efforts by 45% this year, particularly in support of its Pentacel vaccine, an immunization for diphtheria, tetanus and other diseases, and Xyzal, the company's near-blockbuster allergy treatment.
In the US, Sanofi's sponsored meetings and events for pediatricians increased by almost 72% since last year, with almost half of the events promoting Pentacel or Xyzal.
“It's noteworthy that pediatricians' opinions of Sanofi-Aventis US were elevated so much in the course of one year, said Healther Alba, SDI senior product manager, in a statement.
SDI's pharma company image study surveyed close to 10,000 participants, including physicians nurse practitioners, physician assistants and others.